Recruiting

Liberant™ Thrombectomy

Sponsor:

Medtronic Endovascular

Code:

NCT07335341

Conditions

Venous Embolism of Lower Extremities (Diagnosis)

Arterial Embolism and Thrombosis

Acute DVT of Lower Extremity

Chronic DVT of Lower Extremity

DVT

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

Liberant Thrombectomy System

Study Details

Brief summary:

The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Conditions

Venous Embolism of Lower Extremities (Diagnosis)

Arterial Embolism and Thrombosis

Acute DVT of Lower Extremity

Chronic DVT of Lower Extremity

DVT

Study ID

NCT07335341

Start date

Feb 24, 2026

Status verified date

Aug, 2026

Completion date

Oct, 2026

Anticipated

Primary completion date

Oct, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:

1. Patient treated is age ≥ 22 years at the time of procedure
2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Interventions

Liberant Thrombectomy System

The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Primary outcome measure

  • Rate of Device related Serious Adverse Event at Index procedure [ Time Frame: Index Procedure ]
  • Rate of technical success at Index procedure [ Time Frame: Index procedure ]
  • Rate of Procedural Success at Index procedure [ Time Frame: Index procedure ]

Central Contacts and Locations

Central contacts

Manasa Gudipally

763-514-4000manasa.gudipally@medtronic.com

Elizabeth Hunt

elizabeth.m.hunt@medtronic.com

Locations

MedStar Health

Recruiting

Washington D.C., District of Columbia, United States, 003329

Naples Comprehensive Health

Recruiting

Naples, Florida, United States, 34108

Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Manasa Gudipally

manasa.gudipally@medtronic.com

Baylor Heart Hospital Of Plano

Recruiting

Plano, Texas, United States, 75093

Contacts

Manasa Gudipally

manasa.gudipally@medtronic.com

More Information

Sponsor

Medtronic Endovascular

Last update posted

Aug 11, 2026

Last verified

Aug, 2026

Keywords

  • Thrombus in Peripheral Arterial Systems
  • Thrombectomy
  • Thrombosis
  • Venous Thrombosis
  • Aspiration Thrombectomy
  • Percutaneous Mechanical Thrombectomy
  • Arterial Occlusive Diseases
  • Vascular Diseases
  • Peripheral Vascular Diseases
  • Peripheral Arterial Disease
  • Mechanical Thrombectomy
  • Aspiration
  • Liberant Thrombectomy System
  • adverse events
  • Excipio
  • Thrombus in Peripheral Venous Systems

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Medtronic Endovascular on 2026-08-11.